Latest News and Press Releases

HUDDINGE, Sweden, Dec. 9, 2005 (PRIMEZONE) -- Medivir announced today that all rights relating to the development of RP-606 (MIV-606), an oral antiviral being developed for the treatment of herpes...

HUDDINGE, Sweden, Nov. 21, 2005 (PRIMEZONE) -- Medivir (Huddinge, Sweden) and one of China's largest pharmaceutical companies, Jiangsu Hengrui Medicine Company (Shanghai), instigated a two year...

HUDDINGE, Sweden, Oct. 26, 2005 (PRIMEZONE) -- Medivir, Interim Report, 1 January -- 30 September 2005 -- A phase IIa study on MIV-210 against multiresistant HIV began in September. -- A...

HUDDINGE, Sweden, Feb. 18, 2005 (PRIMEZONE) -- Medivir's new issue was fully subscribed in June, raising the company SEK 322.5 m before deducting issue costs. - In July, Medivir and Biovitrum...

HUDDINGE, Sweden, Dec. 27, 2004 (PRIMEZONE) -- Medivir AB announced today that GlaxoSmithKline (GSK) has terminated the research agreement for the developmental HIV compound MIV-210, as the compound...

HUDDINGE, Sweden, Nov. 30, 2004 (PRIMEZONE) -- Medivir AB today announced that it has signed a license and research collaboration agreement on Hepatitis C with Tibotec Pharmaceuticals Ltd, a...

HUDDINGE, Sweden, Oct. 26, 2004 (PRIMEZONE) -- Medivir: - In August, Medivir and Novartis resolved the partly overlapping patent issue on ME-609 (herpes) in the U.S. - The collaboration between...

HUDDINGE, Sweden, Aug. 13, 2004 (PRIMEZONE) -- Medivir and Novartis have resolved the issue of partly overlapping patents in the USA relating to the Medivir ME-609 project by means of a free, two-way...

HUDDINGE, Sweden, July 16, 2004 (PRIMEZONE) -- Medivir and Biovitrum today announce that they initiate a research collaboration to meet the significant and growing medical need in type 2...

HUDDINGE, Sweden, July 06, 2004 (PRIMEZONE) -- Medivir's new share issue was fully subscribed in June, whereby the company raised SEK 322.5 m before deducting issue costs. . A CD (candidate drug)...